Pricing Log in Create free account
Saturday 17 October 2026 Export ZOMDF’s income statement to Excel — free account

Zomedica Corp.

ZOMDF Healthcare Medical Devices

Zomedica Corp.’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 17.4% from fiscal 2024. In the quarter to June 2026, revenue grew 36.6%, EPS grew 49.3% and free cash flow grew 40.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

0.08 0.00 0.00%
Market cap
$95.4M
P/E
0.0×
Fwd P/E
−1.9×
Dividend yield
—
F-score
4/9
Altman Z
0.42
Beneish M
−5.04
Dividend safety
n/a
Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.22
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 4 — — — — — 6 — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 1.76%

Capital & Financial Ratios $m

Market Cap 95.35
Revenue 36.88
Net Income (18.95)
Free Cash Flow (15.03)
Net Debt (44.13)
Current Ratio 6.43 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.85) (negative: loss-making)
P/S ratio 2.13
P/B ratio 0.73
Past 5Y EPS Growth —
This Y EPS Growth (37.14%) (below 0%: weak)
Next Y EPS Growth 37.50% (at or above 15%: strong)
Next Y revenue growth 41.52% (at or above 10%: strong)
Next 5Y EPS Growth 8.29%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.9×, against a ten-year median of 2.3×; over the ten years it ranged from −0.6× in 2025 to 36.3× in 2022.
P/S against its own 10 years 11.55%
10-year low 10-year high
P/B against its own 10 years 29.06%
10-year low 10-year high
EV/Sales against its own 10 years 7.23%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 90 71 53 44
Receivables 2 3 3 6
Inventory 5 5 6 6
Other — — — —
100 82 64 58
2023 2024 2025 Q'26
Payables 2 2 2 2
ST’ Debt — — — —
Other 0 0 0 0
9 9 9 9

Compound Annual Growth %

10y 5y 3y
Sales — — 19.16%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 42.20% 17.71% (24.43%)

Revenue $m

Mar Jun Sep Dec Year
’26 9 10 — — —
’25 7 7 8 10 32
’24 6 6 7 8 27
’23 5 6 6 7 25
’22 4 4 5 6 19
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) (3) — — —
’25 (7) (5) (5) (1) (18)
’24 (8) (7) (5) (5) (24)
’23 (4) (4) (3) (5) (16)
’22 (2) (4) (3) (2) (12)
’21 (3) (2) (5) (5) (14)
’20 (2) (6) (6) (3) (16)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (6) (3) — — —
’25 (7) (6) (5) (1) (19)
’24 (10) (8) (6) (7) (30)
’23 (9) (6) (10) (7) (31)
’22 (3) (4) (4) (3) (14)
’21 (3) (2) (5) (5) (15)
’20 (2) (6) (6) (3) (16)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.00 0.00 — — —
’25 (0.07) (0.01) (0.01) 0.00 (0.08)
’24 (0.01) (0.02) (0.01) (0.01) (0.05)
’23 (0.01) (0.01) 0.00 (0.02) (0.04)
’22 0.00 (0.01) (0.01) 0.00 (0.02)
’21 0.00 0.00 (0.01) 0.00 (0.05)
’20 (0.02) (0.02) (0.01) (0.01) (0.05)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — 1.88 1.04 0.20 0.06 0.25 0.15 0.15 0.12 0.02

Analyst estimates 2026–2028

Powerpack
High — 2.47 2.98 1.27 0.50 2.91 0.50 0.34 0.20 0.16
People
People Employees 20 20 27 28 19 47 85 144 152 141
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.09 0.22 0.17 0.18 0.23
Income, $m
Income, $m Revenue — — — — — 4 19 25 27 32
Gross margin, % 0.00 0.00 0.00 0.00 0.00 73.89 71.15 68.76 69.95 67.68
EBT (6) (8) (17) (20) (17) (21) (19) (36) (48) (82)
EBT margin, % 0.00 0.00 0.00 0.00 0.00 (501.26) (102.38) (142.38) (174.23) (256.43)
Net income (6) (8) (166) (20) (17) (18) (17) (35) (47) (82)
Depreciation 0 0 2 1 1 1 3 4 6 7
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.03 0.03 0.03
Earnings (0.07) (0.09) (0.18) (0.19) (0.05) (0.05) (0.02) (0.04) (0.05) (0.08)
Cash flow (0.06) (0.08) (1.19) (0.15) (0.04) (0.01) (0.01) (0.02) (0.02) (0.02)
Capex 0.00 0.00 (0.07) (0.01) 0.00 0.00 0.00 (0.02) (0.01) 0.00
Free cash flow (0.06) (0.08) (1.26) (0.15) (0.04) (0.02) (0.01) (0.03) (0.03) (0.02)
Book value 0.05 0.05 0.04 0.02 0.14 0.28 0.27 0.24 0.20 0.12
Shares, m 80 87 93 106 364 957 980 980 980 980
Valuation, ×
Valuation, × P/E — — — — — 0.00 0.00 0.00 0.00 0.00
P/S — — — — — 71.75 8.28 7.39 4.31 3.06
P/B — — — — — 1.09 0.59 0.78 0.60 0.85
EV/Sales — — — — — 24.70 2.23 3.82 1.71 1.41
EV/FCF — — — — — (6.90) (2.89) (3.06) (1.54) (2.43)
Cash, $m
Cash, $m Operating cash flow (5) (7) (111) (16) (16) (14) (12) (16) (24) (18)
Capex 0 0 (6) (1) 0 (1) (3) (15) (7) (1)
Free cash flow (5) (7) (118) (16) (16) (15) (14) (31) (30) (19)
Balance, $m
Balance, $m Working capital 3 3 1 0 62 196 116 91 72 55
Total debt — — — — 1 0 1 — — —
Net debt (3) (3) (2) (1) (61) (195) (115) (90) (71) (53)
Shareholders’ equity 4 4 4 2 51 271 267 240 196 115
Returns, %
Returns, % ROA (141.12) (164.74) (295.98) (387.30) (48.09) (29.10) (6.08) (12.96) (20.40) (48.96)
ROIC (588.92) (538.08) (603.60) (780.19) 0.00 (17.59) (9.00) (18.09) (25.67) (84.84)
ROE (158.39) (196.20) (413.91) 637.28 (82.10) (31.32) (6.32) (13.61) (21.57) (52.63)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Zomedica Corp. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
APYX Apyx Medical Corporation $107.8M — (loss-making) — (loss-making) +22.08% (above 0%: growing) n/m −137.38% (below 0%: shrinking) 63.89% (13.01%) Compare
LUCD Lucid Diagnostics Inc. $105.7M — (loss-making) — (loss-making) +26.74% (above 0%: growing) n/m −7.04% (below 0%: shrinking) 1.97% (868.45%) Compare
ZOMDF Zomedica Corp. $95.4M — (loss-making) — (loss-making) +36.59% (above 0%: growing) n/m +40.48% (above 0%: growing) 63.51% (42.92%)
HYPR Hyperfine, Inc. $82.7M — (loss-making) — (loss-making) +44.81% (above 0%: growing) n/m +13.43% (above 0%: growing) 50.72% (216.93%) Compare
SERA Sera Prognostics, Inc. $80.1M — (loss-making) — (loss-making) +76.47% (above 0%: growing) n/m −10.58% (below 0%: shrinking) (66.67%) (33,346.67%) Compare
LUNG Pulmonx Corporation $79.5M — (loss-making) — (loss-making) −4.62% (below 0%: shrinking) n/m −31.79% (below 0%: shrinking) 77.97% (39.80%) Compare
OM Outset Medical, Inc. $76.6M — (loss-making) — (loss-making) +0.69% (above 0%: growing) n/m −90.54% (below 0%: shrinking) 41.99% (49.55%) Compare
ECOR electroCore, Inc. $75.3M — (loss-making) — (loss-making) +28.03% (above 0%: growing) n/m −443.52% (below 0%: shrinking) 86.53% (29.33%) Compare
LNSR LENSAR, Inc. $74.1M 2.0× 7.1× +18.37% (above 0%: growing) n/m +96.81% (above 0%: growing) 59.27% 12.94% Compare
Median of peers $79.8M — — +24.41% — −21.18% 54.99% (44.67%)

All 149 Medical Devices stocks →

Zomedica Corp. (ZOMDF) key facts

  • Strength: Zomedica Corp.’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 17.4% from fiscal 2024.
  • Zomedica Corp. (ZOMDF) is a Medical Devices company in the Healthcare sector.
  • As of October 16, 2026, ZOMDF traded at $0.08, a market capitalization of $95.4 million.
  • Return on equity was −52.6% and debt-to-equity 0.00.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 0.42 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Zomedica Corp. (ZOMDF) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ZOMDF · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com